Idorsia Ltd Appoints Amer Joseph As New Chief Medical Officer And Head of Global Clinical Development, Succeeding Alberto Gimona

Idorsia Ltd announced the appointment of Dr. Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) and Head of Global Clinical Development, effective May 1, 2026. He succeeds Dr. Alberto Gimona, who is retiring after a long and impactful career with the company.

Dr. Joseph brings extensive experience in global clinical development, with a strong record of leading regulatory filings, overseeing mid- and late-stage clinical programs and building high-performing teams. His leadership approach—grounded in scientific rigor, curiosity and a strong sense of accountability—aligns closely with Idorsia’s culture of innovation and agile execution.

In his new role, Dr. Joseph will guide Idorsia’s clinical strategy across all therapeutic areas and ensure strong medical governance. His responsibilities will include advancing the company’s development pipeline, supporting scientific decision-making and shaping the overall medical direction of the organization.

Jean-Paul Clozel, MD, Chairman and interim CEO of Idorsia, welcomed the appointment, noting that Dr. Joseph’s depth of experience, collaborative leadership style and passion for advancing science make him an ideal addition to the company. He emphasized that Dr. Joseph brings the clarity, discipline and patient-focused mindset needed as Idorsia sharpens its scientific priorities and accelerates progress on key programs.

Dr. Joseph shared his enthusiasm for joining the organization, stating that Idorsia’s scientific heritage, culture of innovation and broad clinical pipeline offer significant potential to improve patient lives. He expressed eagerness to collaborate with leadership and teams across the company to advance medicines with scientific rigor and a strong sense of purpose.

As part of this leadership transition, Idorsia extended its deep appreciation to Dr. Alberto Gimona, who is retiring after years of dedicated service, most recently as Head of Global Clinical Development and Medical Affairs. Dr. Gimona played a major role in shaping Idorsia’s development capabilities and advancing important clinical programs. His contributions have left a lasting impact on the company’s scientific progress.

Jean-Paul Clozel also acknowledged Dr. Gimona’s unwavering commitment to science and his support for teams and assets across the organization. He noted that Dr. Gimona leaves behind a meaningful legacy of medicines that have positively impacted many patients and wished him a fulfilling and well-deserved retirement.